Benzinga | Aug 5, 2021 09:14AM EDT

Citigroup Maintains Buy on Horizon Therapeutics, Raises Price Target to $121

Citigroup analyst Navann Ty maintains Horizon Therapeutics (NASDAQ:HZNP) with a Buy and raises the price target from $117 to $121.